Sulfated glycans in inflammation

European Journal of Medicinal Chemistry

Volumn 92, Issue , 2015, Pages 353-369

  Pomin, Vitor H ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Carbohydrate based drug development; Fucoidan; Fucosylated chondroitin sulfate; Glycosaminoglycans; Heparin; Inflammation

Indexed keywords

CARBOHYDRATE; CHONDROITIN SULFATE; DERMATAN SULFATE; FUCOIDIN; GLYCAN DERIVATIVE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARANASE; HEPARIN; HOLOTHURIAN FUCOSYLATED CHONDROITIN SULFATE; IRON; KERATAN SULFATE; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; POLYSACCHARIDE; SULFATE;

ANTIINFLAMMATORY ACTIVITY; BASEMENT MEMBRANE; BLOOD VESSEL PERMEABILITY; BROWN ALGA; CELL MIGRATION; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; COMPETITIVE INHIBITION; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; LEUKOCYTE; LEUKOCYTE ACTIVATION; LEUKOCYTE ROLLING; MOLECULAR INTERACTION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRUCTURE ANALYSIS; SULFATION; SULFONATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; ANIMAL; CHEMISTRY; GREEN ALGA; INFLAMMATION; ISOLATION AND PURIFICATION; RED ALGA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHLOROPHYTA; INFLAMMATION; POLYSACCHARIDES; RHODOPHYTA; SULFATES;

EID: 84920862010     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.01.002     Document Type: Review

References (131)

1. J.B. Lowe, Glycan-dependent leukocyte adhesion and recruitment in inflammation, Curr. Opin. Cell Biol. 15 (2003) 531-538.
2. C.R. Parish, The role of heparan sulphate in inflammation, Nat. Rev. Immunol. 6 (2006) 633-643.
3. K.L. Moore, K.D. Patel, R.E. Bruehl, F. Li, D.A. Johnson, H.S. Lichenstein, R.D. Cummings, D.F. Baiton, R.P. McEver, P-selectin glycoprotein ligand-1 mediates rolling of human neuthrophils on P-selectin, J. Cell Biol. 128 (1995) 661-667.
4. L.M. Webb, M.U. Ehrengruber, I. Clark-Lewis, M. Baggiolini, A. Rot, Binding to heparan sulfate or heparin enhances neuthrophil responses to interleukin 8, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7158-7162.
5. N.S. Gandhi, R.L. Mancera, Molecular dynamics simulations of CXCL-8 and its interactions with a receptor peptide, heparin fragments, and sulfated linked cyclitols, J. Chem. Inf. Model. 51 (2011) 335-358.
6. V.H. Pomin, Biological findings from the recent NMR-based studies of glycosaminoglycan-protein interactions, Glycobiology 24 (2014) 991-1003.
7. V.H. Pomin, Heparin-binding proteins (chemokines and defensins) and their complexes with glycosaminoglycans from the solution nmr perspective, Curr. Protein Pet. Sci. 15 (2014) 738-744.
8. A.J. Hoogewerf, G.S. Kuschert, A.E. Proudfoot, F. Borlat, I. Clark-Lewis, C.A. Power, T.N. Well, Glycosaminoglycans mediate cell surface oligomerization of chemokines, Biochemistry 36 (1997) 13570-13578.
9. X. Wang, J.S. Sharp, T.M. Handel, J.H. Prestegard, Chemokine oligomerization in cell signaling and migration, Prog. Mol. Biol. Transl. Sci. 117 (2013) 531-538.
10. T.M. Handel, Z. Johnson, S.E. Crown, E.K. Lau, A.E. Proudfoot, Regulation of protein function by glycosaminoglcans - as exemplified by chemokines, Annu. Rev. Biochem. 74 (2005) 385-410.
11. S.J. Allen, S.E. Crown, T.M. Handel, Chemokine: receptor structure, interactions, and antagonism, Annu. Rev. Immunol. 25 (2007) 787-820.
12. M. Gotte, Syndecans in in flammation, FASEB J. 17 (2003) 575-591.
13. T.M. Oberyszyn, C.J. Conti, M.S. Ross, A.S. Oberyszyn, K.L. Tober, A.I. Rackoff, F.M. Robertson, Beta2 integrin/ICAM-1 adhesion molecule interactions in cutaneous inflammation and tumor promotion, Carcinogenesis 19 (1998) 445-455.
14. R. Yadav, K.Y. Larbi, R.E. Young, S. Nourshargh, Migration of leukocytes through the vessel wall and beyond, Thromb. Haemost. 90 (2003) 598-606.
15. C.R. Parish, E.J. Hindmarsh, M.R. Bartlett, M.A. Staykova, W.B. Cowden, D.O. Willenborg, Treatment of central nervous system in flammation with inhibitors of basement membrane degradation, Immunol. Cell Biol. 76 (1998) 104-113.
16. D.L. Rabestein, Heparin and heparan sulfate: structure and function, Nat. Prod. Rep. 19 (2002) 312-331.
17. R. Sasisekharan, G. Venkataraman, Heparin and heparan sulfate: biosynthesis, structure and function, Curr. Opin. Struct. Biol. 4 (2000) 626-631.
18. K. Sugahara, H. Kitagawa, Heparin and heparan sulfate biosynthesis, IUBMB Life 54 (2002) 163-175.
19. T.C. Theoharides, K.D. Alysandratos, A. Angelidou, D.A. Delivanis, N. Sismanopoulos, B. Zhang, S. Asadi, M. Vasiadi, Z. Weng, A. Miniati, D. Kalogeromitros, Mast cells and inflammation, Biochim. Biophys. Acta 1822 (2012) 21-33.
20. C. Oschatz, C. Maas, B. Lecher, T. Jansen, J. Björkqvist, T. Tradler, R. Sedlmeier, P. Burfeind, S. Cichon, S. Hammerschmidt, W. Müller-Esterl, W.A. Wuillemin, G. Nilsson, T. Renné, Mast cells increase vascular permeability by heparininitiated bradykinin formation in vivo, Immunity 34 (2011) 258-268.
21. G.R. Santos, A.M. Tovar, N.V. Capillé, M.S. Pereira, V.H. Pomin, P.A. Mourão, Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs, Drug Discov. Today 19 (2014) 1801-1807.
22. D.J. Tyrrell, A.P. Horne, K.R. Holme, J.M. Preuss, C.P. Page, Heparin in inflammation: potential therapeutic applications beyond anticoagulation, Adv. Pharmacol. 46 (1999) 151-208.
23. B.L. Davidson, W.H. Geerts, A.W. Lensing, Low-dose heparin for severe sepsis, N. Engl. J. Med. 347 (2002) 1036-1037.
24. R. Day, A. Forbes, Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease, Lancet 354 (1999) 62-65.
25. D. Hoppensteadt, J. Fareed, A.L. Klein, S.E. Jasper, C. Apperson-Hansen, E.A. Lieber, W.E. Katz, J.F. Malouf, M.F. Stoddard, L.A. Pape, Assessment of cardioversion using transesophageal echocardiography (ACUTE) II investigators. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation, Am. J. Cardiol. 102 (2008) 842-846.
26. T. Ahmed, J. Garrigo, I. Danta, Preventing bronchoconstriction in exerciseinduced asthma with inhaled heparin, N. Engl. J. Med. 329 (1993) 90-95.
27. L. Törkvist, H. Thorlacius, U. Sjöqvist, L. Bohman, A. Lapidus, L. Flood, B. Agren, J. Raud, R. Löfberg, Low molecular weight heparin as adjuvant therapy in active ulcerative colitis, Aliment. Pharmacol. Ther. 13 (1999) 1323-1328.
28. M.J. Saliba Jr., Heparin in the treatment of burns: a review, Burns 27 (2001) 349-358.
29. L. Wang, J.R. Brown, A. Varki, J.D. Esko, Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins, J. Clin. Investig. 110 (2002) 127-136.
30. B.F. Glauser, B.C. Vairo, S.N. Oliveira, L.P. Cinelli, M.S. Pereira, P.A. Mourão, Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug, Thromb. Haemost. 107 (2012) 302-314.
31. J.I. Weitz, Low-molecular-weight heparins, N. Engl. J. Med. 337 (1997) 688-698.
32. F. Gong, X. Cheng, S. Wang, Y. Zhao, Y. Gao, H. Cai, Heparin-immoblized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents, Acta Biomater. 6 (2010) 534-546.
33. N.M. Luan, H. Iwata, Inhibition of instant blood-mediated inflammatory responses by co-immobilization of sCR1 and heparin on islets, Biomaterials 34 (2013) 5019-5024.
34. N. Fontseré, C. Cardoso, J. Donate, A. Soriano, M. Muros, M. Pons, J. Mensa, J.M. Campistol, J.F. Navarro-Gonzáles, F. Maduell, Tunneled catheters with taurolidine-citrate-heparin lock solutions significantly improve the inflammatory profile of hemodialysis patients, Antimicrob. Agents Chemother. 58 (2014) 4180-4184.
35. K.L. Ong, M.L. Villarraga, E. Lau, L.Y. Carreon, S.M. Kurtz, S.D. Glassman, Offlabel use of bone morphogenetic proteins in the United States using administrative data, Spine 36 (2010) 1794-1800.
36. S.E. Kim, S.H. Song, Y.P. Yun, B.J. Choi, I.K. Kwow, M.S. Bae, H.J. Moon, Y.D. Kwon, The effect of immobilization of heparin and bone morphogenic protein-2 (BMP-2) to titanium surfaces on inflammation and osteoblast function, Biomaterials 32 (2011) 366-373.
37. J.B. Huh, S.E. Kim, S.K. Song, M.J. Yun, J.S. Shim, J.Y. Lee, S.W. Shin, The effect of immobilization of heparin and bone morphogenic protein-2 to bovine bone substitute on osteoblast-like cell's function, J. Adv. Prosthodont. 3 (2011) 145-151.
38. J.B. Huh, J.Y. Lee, K.L. Lee, S.E. Kim, M.J. Yun, J.S. Shim, J.S. Shim, S.W. Shin, Effects of the immobilization of heparin and rhPDGF-BB to titanium surfaces for the enhancement of osteoblastic functions and anti-inflammation, J. Adv. Prosthodont. 3 (2011) 152-160.
39. G. Li, P. Yang, X. Guo, N. Huang, R. Shen, An in vitro evaluation of inflammation response of titanium functionalized with heparin/fibronectin complex, Cytokine 56 (2011) 208-217.
40. M. Wang, S.A. Abbah, T. Hu, S.Y. Toh, R.W. Lam, J.C. Goh, H.K. Wong, Minimizing the severity of rhBMP-2-induced inflammation and heterotopic ossification with a polyelectrolyte carrier incorporating heparin on microbead templates, Spine 38 (2013) 1452-1458.
41. H. Badazada, F. Yamashita, S. Yanamoto, M. Hashida, Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR-4-NF-κB-signaling, J. Control Release 194 (2014) 332-340.
42. H. Badazada, F. Yamashita, M. Hashida, Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR-4-NF-κB signaling, J. Control Release 194C (2014) 295-300.
43. V.A. Vasavada, M.R. Praveen, S.K. Shan, R.H. Triverdi, A.R. Vasavada, Anti-inflammatory effect of low-molecular-weight heparin in pediatric cataract surgery: a randomized clinical trial, Am. J. Ophthalmol. 154 (2010) 252-258.
44. J. Sukhija, J. Ram, Anti-inflammatory effect of low-molecular-weight heparin in pediatric cataract surgery, Am. J. Ophthalmol. 154 (2012) 1003-1004.
45. X. Lu, L. Zhao, Y.H. Xu, Low molecular weight heparin prevents CLP-induced acute lung injury in rats by anti-inflammatory coagulation, Bosn. J. Basic Med. Sci. 13 (2013) 50-56.
46. M.D. Shastri, C. Johns, J.P. Hutchinson, M. Khandagale, R.P. Patel, Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties, Anal. Bioanal. Chem. 405 (2013) 6043-6052.
47. Z.G. Luan, M. Naranpurev, X.C. Ma, Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats, Inflammation 37 (2014) 924-932.
48. N. Jiang, W. Xie, H. Wang, D. Jin, H. Tan, C. Zhao, Effects of low molecular weight heparin on the inflammatory response and vascular injury in rat after electric burn, Zhonghua Shao Shang Za Zhi 30 (2014) 128-133.
49. S. Nasiripour, K. Gholami, S. Mousavi, A. Mohagheghi, M. Radfar, M. Abdollahi, Z. Khazaeipour, M. Mojtahedzadeh, Comparison of the effects of enoxaparin and heparin on inflammatory biomarkers in patients with ST-segment elevated myocardial infarction: a prospective open label pilot clinical trial, Iran. J. Pharm. Res. 13 (2014) 583-590.
50. L. Wang, M. Fuster, P. Sriramarao, J. Esko, Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses, Nat. Immunol. 6 (2005) 902-910.
51. J. Axelsson, D. Xu, B.N. Kang, J.K. Nussbacher, T.M. Handel, K. Ley, P. Sriramarao, J.D. Esko, Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice, Blood 120 (2012) 1742-1751.
52. T.M. Reine, M. Kusche-Gullberg, A. Feta, T. Jenssen, S.O. Kolset, Heparan sulfate expression is affected by inflammatory stimuli in primary human endothelial cells, Glycoconj. J. 29 (2012) 67-76.
53. M.E. Strand, K.M. Herum, Z.A. Rana, B. Skrbic, E.T. Askevold, C.P. Dahl, M. Vistnes, A. Hasic, H. Kvaløy, I. Sjaastad, C.R. Carlson, T. Tønnessen, L. Gullestad, G. Christensen, I.G. Lunde, Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart, FEBS J. 280 (2013) 2228-2247.
54. H. Akbarshahi, J.B. Axelsson, K. Said, A. Malmström, H. Fischer, R. Andersson, TLR-4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated, J. Transl. Med. 9 (2011) 219.
55. H.C. Chen, H.T. Chang, P.H. Huang, M.D. Chang, R.S. Liu, Y.J. Lin, C.H. Hsieh, Molecular imaging of heparan sulfate expression with radiolabeled recombinant eosinophil cationic protein predicts allergic lung inflammation in a mouse model for asthma, J. Nucl. Med. 54 (2013) 793-800.
56. R. Lever, A. Smailbegovicm, C.P. Pagem, Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity, Eur. J. Pharmacol. 630 (2010) 137-144.
57. T.S. Lakshmi, N. Shanmugasundaram, S. Shanmuganathan, K. Karthikeyan, J. Meenakshi, M. Babu, Controlled release of 2, 3 desulfated heparin exerts its anti-inflammatory activity by effectively inhibiting E-selectin, J. Biomed. Mater. Res. A 95 (2010) 118-128.
58. T.S. Lakshmi, N. Shanmugasundaram, S. Shanmuganathan, M. Babu, Efficacy of desulfated heparin mitigating inflammation in rat burn wound model, J. Biomed. Mater. Res. B Appl. Biomater. 97 (2011) 215-223.
59. K.L. Griffin, B.M. Fischer, A.B. Kummarapurugu, S. Zheng, T.P. Kennedy, N.V. Rao, W.M. Foster, J.A. Voynow, 2-O, 3-O-desulfated hearin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation, Am. J. Respir. Cell Mol. Biol. 50 (2014) 684-689.
60. N.V. Rao, B. Argyle, X. Xu, P.R. Reynolds, J.M. Walenga, M. Prechel, G.D. Prestwich, R.B. MacArthur, B.B. Walters, J.R. Hoidal, T.P. Kennedy, Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands, Am. J. Physiol. Cell Physiol. 299 (2010) C97-C110.
61. X. Li, Z. Zheng, X. Li, X. Ma, Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-kB activation on endothelial cell, Cytokine 60 (2012) 114-121.
62. X. Li, X. Li, Z. Zheng, X. Ma, Unfractionated heparin ameliorates lipopolysaccharide-induced lung inflammation by downregulating nuclear factor-kB signaling pathway, Inflammation 36 (2013) 1201-1208.
63. J.H. Kang, S.R. Hwang, S. Sung, J.A. Jang, M.M. Alam, K.H. Sa, S.Y. Kim, I.S. Kim, Y.R. Byun, Y.M. Kang, Intracellular delivery of desulfated heparin with bile acid conjugation alleviates T cell-mediated inflammatory arthritis via inhibition of RhoA-dependent transcellular diapedesis, J. Control Release 183 (2014) 9-17.
64. C. Makino-Okamura, Y. Niki, S. Takeuchi, C. Nishigori, L. Declercq, D.B. Yaroch, N. Saito, Heparin inhibits melanosome uptake and inflammatory response coupled with phagocytosis through blocking Pl3k/Akt and MEK/ERK signaling pathways in human epidermal keratinocytes, Pigment Cell Melanoma Res. 27 (2014) 1063-1074.
65. B. Casu, A. Naggi, G. Torri, Heparin-derived heparan sulfate mimetics to modulate heparan sulfate-protein interaction in inflammation and cancer, Matrix Biol. 29 (2010) 442-452.
66. J.P. Li, I. Vlodavsky, Heparin, heparan sulfate and heparanase in inflammatory reactions, Thromb. Haemost. 102 (2009) 823-828.
67. H. Saffari, J.J. Krstyen, C. Gonzalez, F.C. Clayton, K.M. Leiferman, G.J. Gleich, K.A. Peterson, L.F.3rd. Pease, 99mTechnetium-labeled heparin: a new approach to detection of eosinoplilic esophagitis-associated inflammation, J. Allergy Clin. Immunol. 132 (2013) 1446-1448.
68. V. Ferro, Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses, Expert Opin. Ther. Targets 17 (2013) 965-975.
69. M. Tong, B. Tuk, I.M. Hekking, M. Vermeij, D. Barritault, J.W. van Neck, Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120, Wound Repair Regen. 17 (2009) 840-852.
70. H.M. Sun, Y. Shi, Y. Song, X.Q. Lin, X.K. Shen, L.Z. Hong, Effect of heparin upon inflammatory reaction of endotoxin-induced acute lung injury in rat, Zhonghua Yi Xue Za Zhi 89 (2009) 2722-2725.
71. N. Chande, J.K. MacDonald, J.J. Wang, J.W. McDonald, Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane in fl ammatory bowel disease and functional bowel disorders systematic review of randomized trials, Inflamm. Bowel Dis. 17 (2011) 1979-1986.
72. D. Zhao, R. Dingm, Y. Mao, L. Wang, Z. Zhang, X. Ma, Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses, Inflammation 35 (2012) 1825-1832.
73. R. Ding, D. Zhao, R. Guo, Z. Zhang, X. Ma, Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice, Thromb. Res. 128 (2011) e1160-165.
74. G. Johnson, B. Curry, L. Cahalan, R. Prater, J. Biggerstaff, A. Hussain, M. Gartner, P. Cahalan, Effects of surface-bound and intravenously administered heparin on cell-surface interactions: inflammation and coagulation, Perfusion 28 (2013) 263-271.
75. Y.O. Bicer, S. Koybasi, A.E. Suslu, A. Kukner, E. Tezcan, N. Ulas, Effect of heparin on inflammation: an animal model of tracheal stents, Laryngoscope 124 (2014) E368-E372.
76. L.S. Fu, J.J. Tsai, Y.J. Chen, H.K. Lin, M.C. Tsai, M.D. Chang, Heparin protects BALB/c mice from mite-induced airway allergic inflammation, Int. J. Immunopathol. Pharmacol. 26 (2013) 349-359.
77. Z.Y. Wang, B.X. Yang, X. Zhu, S.N. Wu, Effect of inhalation of aerosolized unfractionated heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 23 (2011) 239-242.
78. Z.Y. Wang, S.N. Wu, X. Zhu, The effects of three dosages of nebulized unfractionated heparin on alveolar coagulation and tissue inflammation injury in endotoxin-induced acute lung injury rat models, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 24 (2012) 612-615.
79. Z.Y. Wang, S.N. Wu, Z.Z. Zhu, B.X. Yang, X. Zhu, Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats, Chin. Med. J. Engl. 126 (2013) 318-324.
80. A. Yildiz, E. Johnm, Y. Özsoy, A. Araman, J.C. Birchall, K.J. Broadley, M. Gumbleton, Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation, J. Control Release 162 (2012) 456-463.
81. K. Sugahara, T. Mikami, T. Uyama, S. Mizuguchi, K. Nomura, H. Kitagawa, Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate, Curr. Opin. Struct. Biol. 13 (2003) 612-620.
82. M. Vallières, P. du Souich, Modulation of inflammation by chondroitin sulfate, Osteoarthr. Cartil. Suppl. 1 (2010) S1-S6.
83. N. Volpi, Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule, Inflammopharmacology 19 (2011) 299-306.
84. E.D. Kantor, J.W. Lampe, S.L. Navarro, X. Song, G.L. Milne, E. White, Associations between glucosamine and chondroitin supplement use and biomarker of systemic inflammation, J. Altern. Complement. Med. 20 (2014) 479-485.
85. V.H. Pomin, A.P. Piquet, M.S. Pereira, P.A. Mourão, Residual keratan sulfate in chondroitin sulfate formulations for oral administration, Carbohydr. Polym. 90 (2012) 839-846.
86. C. Rubio-Terrés, Grupo del estudio VECTRA, An economic evaluation of chondroitin sulfate and non-steroidal anti-inflammatory drugs for the treatment of osteoarthritis. Data from the VECTRA study, Reumatol. Clin. 6 (2010) 187-195.
87. E.O. Kozlowski, M.S. Pavão, L. Borsig, Ascidian dermatan sulfates attenuates metastasis, inflammation and thrombosis by inhibition of P-selection, J. Thromb. Haemost. 9 (2011) 1807-1815.
88. N. Cañas, R. Gorina, A.M. Planas, J. Vergés, E. Montell, A.G. García, M.G. López, Chondroitin sulfate inhibits lipopolysaccharide-induced inflammation in rat astrocytes by preventing nuclear factor kappa B activation, Neuroscience 167 (2010) 872-879.
89. G.K. Tan, Y. Tabata, Chondroitin-6-sulfate attenuates inflammatory responses in murine macrophages via suppression of NF-kB nuclear translocation, Acta Biomater. 10 (2014) 2684-2692.
90. O. Craciunescu, L. Moldovan, M. Moisei, M. Trif, Liposomal formulation of chondroitin sulfate enhances its antioxidant and anti-inflammatory potential in L929 fibroblast cell line, J. Liposome Res. 23 (2013) 145-153.
91. C.D. Engles, P.J. Hauser, S.N. Abdullah, D.J. Culkin, R.E. Hurst, Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage "leaky bladder" model of cystitis, Urology 79 (2012) 483.e13-483.e17.
92. V. Calamia, L. Lourido, P. Fernández-Puente, J. Mateos, B. Rocha, E. Montell, J. Vergés, C. Ruiz-Romero, F.J. Blanco, Secretome analysis of chondroitin sulftae-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties, Arthritis Res. Ther. 14 (2012) R202.
93. B. Ruffell, G.F. Poon, S.S. Lee, K.L. Brown, S.L. Tjew, J. Copper, P. Johnson, Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in inflammatory and interleukin 4-activated macrophages, J. Biol. Chem. 286 (2011) 19179-19190.
94. C.L. Belmiro, R.G. Gonc¸alves, E.O. Kozlowski, A.F. Werneck, C.M. Takyia, M. Leite- Jr., M.S. Pavão, Dermatan sulfate reduces monocyte chemoattractant protein 1 and TGF-β production, as well as macrophage recruitment and myofibroblast accumulation in mice with unilateral ureteral obstruction, Braz. J. Med. Biol. Res. 44 (2011) 624-633.
95. J.A. Godoy, D.B. Block, D.M. Tollefsen, C.C. Werneck, C.P. Vicente, Dermatan sulfate and bone marrow mononuclear cells used as a new therapeutic strategy after arterial injury in mice, Cytotherapy 13 (2011) 695-704.
96. K. Winsz-Szczotka, K. Komosińska-Vassev, K. Kuźnik-Trocha, A. Siwiec, B. Zegleń, K. Olczyk, Circulating keratan sulfate as a marker of metabolic changes of cartilage proteoglycan in juvenile idiopathic arthritis; influence of growth factors as well as proteolytic and prooxidative agents on aggrecan alterations, Clin. Chem. Lab. Med. (2014) (in press).
97. H. Matsui, T. Ohgomori, T. Natori, K. Miyamoto, S. Kusunoki, K. Sakamoto, N. Ishiguro, S. Imagama, K. Kadomatsu, Keratan sulfate expression in microglia is diminished in the spinal cord in experimental autoimmune neuritis, Cell Death Dis. 4 (2013) e946.
98. E.C. Carlson, Y. Sun, J. Auletta, W.W. Kao, C.Y. Liu, V.L. Perez, E. Pearlman, Regulation of corneal inflammation by neutrophil-dependent cleavage of keratan sulfate proteoglycans as a model for breakdown of the chemokine gradient, J. Leukoc. Biol. 88 (2010) 517-522.
99. K. Shirato, C. Gao, F. Ota, T. Angata, H. Shogomori, K. Ohtsubo, K. Yoshida, B. Lepenies, N. Taniguchi, Flagellin/Toll-like receptor 5 response was specifically attenuated by keratan sulfate disaccharide via decreased EGFR phosphorylation in normal human bronchial epithelial cells, Biochem. Biophys. Res. Commun. 435 (2013) 460-465.
100. M. Hayashi, K. Kadomatsu, N. Ishiguro, Keratan sulfate suppresses cartilage damage and ameliorates in fl ammation in an experimental mice arthritis model, Biochem. Biophys. Res. Commun. 401 (2010) 463-468.
101. M. Hayashi, K. Kadomatsu, T. Kojima, N. Ishiguro, Keratan sulfate and related murine glycosylation can suppress murine cartilage damage in vitro and in vivo, Biochem. Biophys. Res. Commun. 409 (2011) 732-737.
102. V.H. Pomin, Holothurian fucosylated chondroitin sulfate, Mar. Drugs 12 (2014) 232-254.
103. V.H. Pomin, Fucanomics and galactanomics: current status in drug discovery, mechanisms of action and role of the well-defined structures, Biochim. Biophys. Acta 1820 (2012) 1971-1979.
104. L. Ye, L. Xu, J. Li, Preparation and anticoagulant activity of a fucosylated polysaccharide sulfate from a sea cucumber Acaudina molpadioidea, Carbohydr. Polym. 87 (2012) 2052-2057.
105. H. Nagase, K.-I. Enjyoji, K. Minamiguchi, K.T. Kitazato, K. Kitazato, H. Saito, H. Kato, Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin, Blood 85 (1995) 1527-1534.
106. H.-I. Yoshida, Y. Minami, Structure of DHG, a depolymerized holothurian glycosaminoglycan from sea cucumber, Stichopus japonicus, Tetrahedron Lett. 33 (1992) 4959-4962.
107. R.J. Fonseca, G.R. Santos, P.A. Mourão, Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications, Thromb. Haemost. 102 (2009) 829-836.
108. P.A. Mourão, M.S. Pereira, M.S. Pavão, B. Mulloy, D.M. Tollefsen, M.C. Mowinckel, U. Abildgaard, Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action, J. Biol. Chem. 271 (1996) 23973-23984.
109. S. Chen, C. Xue, L. Yin, Q. Tang, G. Yu, W. Chai, Comparison of structures and anticoagulant activities of fucosylated chondroitin sulfates from different sea cucumbers, Carbohydr. Polym. 83 (2011) 688-696.
110. L. Luo, M. Wu, L. Xu, W. Lian, J. Xiang, F. Lu, N. Gao, C. Xiao, S. Wang, J. Zhao, Comparison of physicochemical characteristics and anticoagulant activities of polysaccharides from three sea cucumbers, Mar. Drugs 11 (2013) 399-417.
111. C. Panagos, D.S. Thomson, C. Moss, A.D. Hughes, M.S. Kelly, Y. Liu, W. Chai, R. Venkatasamy, D. Spina, C.P. Page, J. Hogwood, R.J. Woods, B. Mulloy, C.D. Bavington, D. Uhrin, Fucosylated chondroitin sulfates from the body wall of the sea cucumber Holothuria forskali. Conformation, selectin binding and biological activity, J. Biol. Chem. 289 (2014) 28284-28298.
112. N.M. Melo-Filho, C.L. Belmiro, R.G. Gonc¸alves, C.M. Takiya, M. Leite Jr., M.S. Pavão, P.A. Mourão, Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event? Am. J. Physiol. Ren. Physiol. 299 (2010) F1299-F1307.
113. L. Borsig, L. Wang, M.C. Cavalcante, L. Cardilo-Reis, P.L. Ferreira, P.A. Mourão, J.D. Esko, M.S. Pavão, Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment, J. Biol. Chem. 282 (2007) 14984-14991.
114. V.H. Pomin, Review: an overview about the structure-function relationship of marine sulfated homopolysaccharides with regular chemical structures, Biopolymers 91 (2009) 601-609.
115. V.H. Pomin, P.A. Mourão, Structure, biology, evolution and medical importance of sulfated fucans and galactans, Glycobiology 18 (2008) 1016-1027.
116. V.H. Pomin, Fucanomics and galactanomics: marine distribution, medicinal impact, conceptions, and challenges, Mar. Drugs 10 (2012) 793-811.
117. M.I. Bilan, E.V. Vinogradova, A.S. Shashkov, A.I. Usov, Structure of a highly pyruvylated galactan sulfate from the Pacific green alga Codium yezoense (Bryopsidales, Chlorophyta), Carbohydr. Res. 342 (2007) 586-596.
118. E.H. Farias, V.H. Pomin, A.P. Valente, H.B. Nader, H.A. Rocha, P.A. Mourão, A preponderantly 4-sulfated, 3-linked galactan from the green alga Codium isthmocladum, Glycobiology 18 (2008) 250-259.
119. V.H. Pomin, Structural and functional insights into sulfated galactans: a systematic review, Glycoconj. J. 27 (2010) 1-12.
120. A. Cumashi, N.A. Ushakova, M.E. Preobrazhenskaya, A. D'Incecco, A. Piccoli, L. Totani, N. Tinari, G.E. Morozevich, A.E. Berman, M.I. Bilan, A.I. Usov, N.E. Ustyuzhanina, A.A. Grachev, C.J. Sanderson, M. Kelly, G.A. Rabinovich, S. Iacobelli, N.E. Nifantiev, Consorzio Interuniversitario Nazionale per la Bio-Oncologia, Italy. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds, Glycobiology 17 (2007) 541-552.
121. J.I. Choi, H.R. Raghavendran, N.Y. Sung, J.H. Kim, B.S. Chun, D.H. Ahn, H.S. Choi, K.W. Kang, J.W. Lee, Effect of fucoidan on aspirin-induced stomach ulceration in rats, Chem. Biol. Interact. 183 (2010) 249-254.
122. M. Mizuno, Y. Nishitani, T. Hashimoto, K. Kanazawa, Different suppressive effects of fucoidan and lentinan on IL-8 mRNA expression in in vitro gut inflammation, Biosci. Biotechnol. Biochem. 73 (2009) 2324-2325.
123. K.J. Kim, B.Y. Lee, Fucoidan from the sporophyll of Undaria pinnatifida suppresses adipocyte differentiation by inhibition of inflammation-related cytokines in 3T3-L1 cells, Nutr. Res. 32 (2012) 439-447.
124. A.C. Carvalho, R.B. Sousa, Á.X. Franco, J.V. Costa, L.M. Neves, R.A. Ribeiro, R. Sutton, D.N. Criddle, P.M. Soares, M.H. de Souza, Protective effects of fucoidan, a P- and L-selectin inhibitor, in murine acute pancreatitis, Pancreas 43 (2014) 82-87.
125. H.Y. Park, M.H. Han, C. Park, C.Y. Jin, G.Y. Kim, I.W. Choi, N.D. Kim, T.J. Nam, T.K. Kwon, Y.H. Choi, Anti-inflammatory effects of fucoidan through inhibition of NF-κB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells, Food Chem. Toxicol. 49 (2011) 1745-1752.
126. Y.Q. Cui, Y.J. Jia, T. Zhang, Q.B. Zhang, X.M. Wang, Fucoidan protects against lipopolysaccharide-induced rat neuronal damage and inhibits the production of proinflammatory mediators in primary microglia, CNS Neurosci. Ther. 18 (2012) 827-833.
127. C. Li, Y. Gao, Y. Xing, H. Zhu, J. Shen, J. Tian, Fucoidan, a sulfated polysaccharide from brown algae, against myocardial ischemia-reperfusion injury in rats via regulating the inflammation response, Food Chem. Toxicol. 49 (2011) 2090-2095.
128. S.H. Lee, C.I. Ko, G. Ahn, S. You, J.S. Kim, M.S. Heu, J. Kim, Y. Jee, Y.J. Jeon, Molecular characteristics and anti-inflammatory activity of the fucoidan extracted from Ecklonia cava, Carbohydr. Polym. 89 (2012) 599-606.
129. S.H. Lee, C.I. Ko, Y. Jee, Y. Jeong, M. Kim, J.S. Kim, Y.J. Jeon, Anti-inflammatory effect of fucoidan extracted from Ecklonia cava in zebrafish model, Carbohydr. Polym. 92 (2013) 84-89.
130. J. Kyung, D. Kim, D. Park, Y.H. Yang, E.K. Choi, S.P. Lee, T.S. Kim, Y.B. Lee, Y.B. Kim, Synergistic anti-inflammatory effects of Laminaria japonica fucoidan and Cistanche tubulosa extract, Lab. Anim. Res. 28 (2012) 91-97.
131. A.A. de Sousa, N.M. Benevides, A. de Freitas Pires, F.P. Fiúza, M.G. Queiroz, T.M. Morais, M.G. Pereira, A.M. Assreuy, A report of a galactan from marine alga Gelidium crinale with in vivo anti-inflammatory and antinociceptive effects, Fundam. Clin. Pharmacol. 27 (2013) 173-180.